Akademska digitalna zbirka SLovenije - logo
E-viri
Recenzirano Odprti dostop
  • IL-27 Counteracts Neuropath...
    Fonseca, Miriam M; Davoli-Ferreira, Marcela; Santa-Cecília, Flávia; Guimarães, Rafaela M; Oliveira, Francisco F B; Kusuda, Ricardo; Ferreira, David W; Alves-Filho, José C; Cunha, Fernando Q; Cunha, Thiago M

    Frontiers in immunology, 01/2020, Letnik: 10
    Journal Article

    Neuroimmune-glia interactions have been implicated in the development of neuropathic pain. Interleukin-27 (IL-27) is a cytokine that presents regulatory activity in inflammatory conditions of the central nervous system. Thus, we hypothesized that IL-27 would participate in the neuropathic pain process. Here, we found that neuropathic pain caused by peripheral nerve injury (spared nerve injury model; SNI), was enhanced in IL-27-deficient mice, whereas nociceptive pain is similar to that of wild-type mice. SNI induced an increase in the expression of IL-27 and its receptor subunit ( ) in the sensory ganglia and spinal cord. IL-27 receptor was expressed mainly in resident macrophage, microglia, and astrocytes of the sensory ganglia and spinal cord, respectively. Finally, we identify that the antinociceptive effect of IL-27 was not observed in IL-10 mice. These results provided evidence that IL-27 is a cytokine produced after peripheral nerve injury that counteracts neuropathic pain development through induction of the antinociceptive cytokine IL-10. In summary, our study unraveled the role of IL-27 as a regulatory cytokine that counteracts the development of neuropathic pain after peripheral nerve damage. In conclusion, they indicate that immunotherapies based on IL-27 could emerge as possible therapeutic approaches for the prevention of neuropathic pain development after peripheral nerve injury.